Corticosteroid Treatment in Diabetic Macular Edema
Diabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial. For many years, laser photocoagulation has been considered the standard therapy for the treatment of diabetic macular edema; howev...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2017-06-01
|
| Series: | Türk Oftalmoloji Dergisi |
| Subjects: | |
| Online Access: | http://oftalmoloji.org/article_14970/Corticosteroid-Treatment-In-Diabetic-Macular-Edema |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308565239496704 |
|---|---|
| author | Burcu Nurözler Tabakcı Nurten Ünlü |
| author_facet | Burcu Nurözler Tabakcı Nurten Ünlü |
| author_sort | Burcu Nurözler Tabakcı |
| collection | DOAJ |
| description | Diabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial. For many years, laser photocoagulation has been considered the standard therapy for the treatment of diabetic macular edema; however, few patients achieve significant improvements in visual acuity. Today the intravitreal administration of anti-inflammatory or anti-angiogenic agents together with the use of laser photocoagulation represents the standard of care for the treatment of this complication. The intravitreal route of administration minimizes the systemic side effects of corticosteroids. Steroid-related ocular side effects are elevated intraocular pressure and cataract, while injection-related complications include endophthalmitis, vitreous hemorrhage, and retinal detachment. In order to reduce the risks and complications, intravitreal implants have been developed recently to provide sustained release of corticosteroids and reduce repeated injections for the management of diabetic macular edema. In this review, the efficacy, safety, and therapeutic potential of intravitreal corticosteroids in diabetic macular edema are discussed with a review of recent literature. |
| format | Article |
| id | doaj-art-043aeff053c84fbe87405a8fa4646d9d |
| institution | Kabale University |
| issn | 1300-0659 2147-2661 |
| language | English |
| publishDate | 2017-06-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Türk Oftalmoloji Dergisi |
| spelling | doaj-art-043aeff053c84fbe87405a8fa4646d9d2025-08-20T03:54:25ZengGalenos Publishing HouseTürk Oftalmoloji Dergisi1300-06592147-26612017-06-0147315616010.4274/tjo.56338Corticosteroid Treatment in Diabetic Macular EdemaBurcu Nurözler Tabakcı 0Nurten Ünlü1Ağrı State Hospital, Ophthalmology Clinic, Ağrı, TurkeyAnkara Training and Research Hospital, Ophthalmology Clinic, Ankara, TurkeyDiabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial. For many years, laser photocoagulation has been considered the standard therapy for the treatment of diabetic macular edema; however, few patients achieve significant improvements in visual acuity. Today the intravitreal administration of anti-inflammatory or anti-angiogenic agents together with the use of laser photocoagulation represents the standard of care for the treatment of this complication. The intravitreal route of administration minimizes the systemic side effects of corticosteroids. Steroid-related ocular side effects are elevated intraocular pressure and cataract, while injection-related complications include endophthalmitis, vitreous hemorrhage, and retinal detachment. In order to reduce the risks and complications, intravitreal implants have been developed recently to provide sustained release of corticosteroids and reduce repeated injections for the management of diabetic macular edema. In this review, the efficacy, safety, and therapeutic potential of intravitreal corticosteroids in diabetic macular edema are discussed with a review of recent literature.http://oftalmoloji.org/article_14970/Corticosteroid-Treatment-In-Diabetic-Macular-EdemaDiabetic macular edemaintravitreal corticosteroidtriamcinolone acetonidedexamethasonefluocinolone acetonide |
| spellingShingle | Burcu Nurözler Tabakcı Nurten Ünlü Corticosteroid Treatment in Diabetic Macular Edema Türk Oftalmoloji Dergisi Diabetic macular edema intravitreal corticosteroid triamcinolone acetonide dexamethasone fluocinolone acetonide |
| title | Corticosteroid Treatment in Diabetic Macular Edema |
| title_full | Corticosteroid Treatment in Diabetic Macular Edema |
| title_fullStr | Corticosteroid Treatment in Diabetic Macular Edema |
| title_full_unstemmed | Corticosteroid Treatment in Diabetic Macular Edema |
| title_short | Corticosteroid Treatment in Diabetic Macular Edema |
| title_sort | corticosteroid treatment in diabetic macular edema |
| topic | Diabetic macular edema intravitreal corticosteroid triamcinolone acetonide dexamethasone fluocinolone acetonide |
| url | http://oftalmoloji.org/article_14970/Corticosteroid-Treatment-In-Diabetic-Macular-Edema |
| work_keys_str_mv | AT burcunurozlertabakcı corticosteroidtreatmentindiabeticmacularedema AT nurtenunlu corticosteroidtreatmentindiabeticmacularedema |